Table 3.

Quantitative comparison is performed for prostate cases, where we assess target coverage, dose homogeneity, conformity, spillage, and OAR sparing. Methods are compared using the Wilcoxon signed-rank test (p < 0.05) with the best values bolded for readability.

	PTV			R90	R50	OAR	Mean Dose (μ)	D(2%) (Gy)	D(20%) (Gy)	D(40%) (Gy)
	D 95	HI	CI
Manual VMAT (~360 CPs)	72.0 (0.0)	4.63 (0.98)	0.86 (0.03)	1.29 (0.05)	3.44 (0.20)	Rectum	29.2 (5.4)	73.3 (2.6)	49.7 (10.1)	30.3 (7.3)
						Bladder	18.6 (9.3)	71.0 (6.5)	34.4 (20.4)	14.5 (11.5)
						FH R	15.9 (3.3)	30.5 (5.1)	23.3 (4.6)	19.0 (4.2)
						FH L	14.5 (3.1)	29.7 (5.1)	21.5 (4.5)	16.7 (3.3)
						Body	3.8 (0.8)	34.1 (6.6)	3.1 (1.5)	0.5 (0.2)
MP VMAT (~120 CPs)	72.0 (0.0)	4.14 (0.62)	0.90 (0.01)	1.24 (0.03)	3.26 (0.17)	Rectum	27.8 (8.0)	72.0 (6.7)	44.9 (13.5)	28.1 (9.8)
						Bladder	19.1 (9.9)	71.8 (5.6)	36.1 (19.5)	15.2 (13.1)
						FH R	12.7 (2.0)	23.3 (2.2)	18.3 (1.9)	15.2 (2.0)
						FH L	12.6 (1.6)	23.7 (2.0)	18.6 (1.6)	15.3 (1.5)
						Body	3.5 (0.7)	33.6 (5.5)	2.2 (1.4)	0.1 (0.0)
MP Boosted VMAT (~90 CPs)	72.0 (0.0)	4.17 (0.59)	0.91 (0.01)	1.23 (0.03)	3.27 (0.15)	Rectum	27.5 (8.2)	71.9 (7.0)	44.4 (13.7)	27.7 (10.1)
						Bladder	18.6 (9.6)	71.8 (5.5)	35.5 (19.7)	14.4 (12.8)
						FH R	13.1 (2.3)	23.2 (2.2)	18.5 (2.1)	15.7 (2.5)
						FH L	13.1 (1.6)	23.8 (2.1)	19.0 (1.5)	16.0 (1.4)
						Body	3.4 (0.7)	33.9 (5.6)	2.1 (1.3)	0.1 (0.0)

	PTV		R90	R50	Rectum (μ)	Bladder (μ)	FH R (μ)	FH L (μ)	Body (μ)
	HI	CI
MP Boosted VMAT vs. Manual VMAT (p-value)	0.22883	0.00226	0.00059	0.00312	0.19243	0.79434	0.00130	0.02281	0.00007
MP Boosted VMAT vs. MP VMAT (p-value)	0.31731	0.00082	0.02820	0.34768	0.27358	0.02081	0.09874	0.00414	0.04202
MP VMAT vs. Manual VMAT (p-value)	0.13037	0.00001	0.00001	0.13962	0.52021	0.18084	0.00006	0.00016	0.00009